Equities

MicroTech Medical Hangzhou Co Ltd

MicroTech Medical Hangzhou Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)4.08
  • Today's Change0.00 / 0.00%
  • Shares traded34.90k
  • 1 Year change-40.44%
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024 08:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MicroTech Medical Hangzhou Co Ltd is a China-based company that mainly engaged in research, production and commercialization of diabetes treatment and diabetes monitoring. The Company's products such as applicator insulin pump system (Equil), blood glucose monitoring system and continuous blood glucose monitoring system (AiDEX G7) have been commercialized. The Company's products, such as artificial pancreas, are in the process of research and development. The Company's products are sold to overseas markets such as the United States and the European Union.

  • Revenue in HKD (TTM)229.28m
  • Net income in HKD-49.37m
  • Incorporated2011
  • Employees760.00
  • Location
    MicroTech Medical Hangzhou Co LtdNo. 108 Liuze StreetCangqian Street, Yuhang DistrictHANGZHOU ChinaCHN
  • Websitehttps://www.microtechmd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Austar Lifesciences Ltd1.90bn-35.18m363.93m1.61k--0.436431.210.1913-0.0686-0.23883.711.630.77573.901.801,181,793.00-1.534.39-3.449.9819.0523.09-1.974.561.13-1.660.3902---18.2316.65-131.28------
China Health Group Ltd74.43m-29.50m407.15m133.00--5.41--5.47-0.0651-0.06510.16410.15720.25363.823.03543,313.90-9.74-10.57-17.56-21.4233.6233.05-38.40-32.700.9156-4.910.0765---28.6025.81-244.50--50.63--
Shanghai Bio-heart Biologicl Tech Co Ltd0.00-189.75m517.15m32.00--0.6405-----0.7787-0.77870.003.310.00----0.00-20.99---22.30----------20.16--0.0023------13.88------
Ziyuanyuan Holdings Group Ltd537.19m15.71m709.50m184.0042.011.9623.361.320.03930.03931.340.84270.81844.543.022,919,487.002.282.613.673.7124.69--2.786.131.752.260.313--53.4152.48-7.90-2.98----
Shanghai HeartCare Medcl Tech Corp Ltd250.65m-101.42m744.84m368.00--0.6419--2.97-2.66-2.666.5829.880.18490.49314.54681,111.10-7.48---7.88--70.48---40.46--14.37--0.0327--26.94--53.08------
Guanze Medical Infrm Indstry (Hldng) Ltd168.37m29.74m883.50m56.0029.713.0424.145.250.03130.03130.17720.30590.48765.371.183,006,570.008.72--10.54--54.72--17.89--6.2552.600.0748---11.88--53.63------
PW Medtech Group Ltd728.27m165.25m1.55bn1.24k9.380.35534.742.130.10560.10560.46522.790.13312.199.21585,425.604.047.234.918.0956.4258.1330.3785.3812.70--0.00024.1125.7516.7844.465.94-7.92--
MicroTech Medical Hangzhou Co Ltd229.28m-49.37m1.74bn760.00--0.7339--7.58-0.116-0.1160.53855.560.09281.906.77301,680.40-2.00---2.06--49.32---21.53--31.33--0.0002--45.92---256.75------
Sisram Medical Ltd2.81bn246.02m1.85bn1.08k7.540.5255.040.66090.52530.52535.997.540.61471.804.392,598,380.005.635.946.706.8861.1057.669.1610.582.0013.960.086928.791.3618.48-21.597.61--9.64
ClouDr Group Ltd3.98bn-348.52m1.94bn1.52k--0.8982--0.4866-0.6442-0.64427.363.671.285.484.742,615,827.00-11.33---17.13--24.64---8.87--1.58-29.150.1314--23.51--80.87------
Jenscare Scientific Co Ltd0.00-401.02m2.16bn376.00--1.62-----0.9613-0.96130.003.190.00----0.00-27.49---28.61----------19.20--0.0347------15.38------
Venus MedTech HangZhou Inc530.09m-759.20m2.48bn865.00--0.7866--4.68-1.73-1.731.217.140.10140.94021.65612,815.10-15.04-13.20-17.41-14.9779.2179.51-148.37-152.831.86-8.780.2206--20.8933.6233.46--58.20--
IVD Medical Holding Ltd3.33bn256.93m2.52bn803.009.790.69828.500.75620.190.192.462.660.67882.785.624,149,067.005.215.186.866.6721.7520.757.687.531.567.530.0923--12.3549.4913.4118.1519.77--
Data as of May 07 2024. Currency figures normalised to MicroTech Medical Hangzhou Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

11.40%Per cent of shares held by top holders
HolderShares% Held
Invesco Advisers, Inc.as of 18 Nov 20228.48m4.88%
UBS Asset Management (Hong Kong) Ltd.as of 31 Jan 20244.36m2.51%
Fidelity Management & Research (Hong Kong) Ltd.as of 17 Nov 20223.35m1.93%
Carmignac Gestion SAas of 31 Dec 20232.77m1.60%
Fidelity Management & Research Co. LLCas of 29 Feb 2024414.01k0.24%
Norges Bank Investment Managementas of 31 Dec 2023394.40k0.23%
China Universal Asset Management Co., Ltd.as of 31 Dec 202246.30k0.03%
China Southern Asset Management Co., Ltd.as of 30 Jun 20230.000.00%
Bin Yuan Capital Ltd. (Hong Kong)as of 31 Mar 20230.000.00%
More ▼
Data from 31 Mar 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.